Vertex Pharmaceuticals Inc (VRTX)
397.70
-3.06
(-0.76%)
USD |
NASDAQ |
Apr 25, 16:00
397.77
+0.07
(+0.02%)
After-Hours: 20:00
Vertex Pharmaceuticals Cash from Financing (TTM): -562.20M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -562.20M |
| September 30, 2023 | -402.20M |
| June 30, 2023 | -297.40M |
| March 31, 2023 | -267.00M |
| December 31, 2022 | -67.70M |
| September 30, 2022 | -444.10M |
| June 30, 2022 | -1.041B |
| March 31, 2022 | -1.055B |
| December 31, 2021 | -1.478B |
| September 30, 2021 | -1.267B |
| June 30, 2021 | -751.00M |
| March 31, 2021 | -664.57M |
| December 31, 2020 | -505.30M |
| September 30, 2020 | -218.64M |
| June 30, 2020 | -57.60M |
| March 31, 2020 | -190.64M |
| December 31, 2019 | 126.80M |
| September 30, 2019 | -135.69M |
| June 30, 2019 | -153.97M |
| March 31, 2019 | -192.16M |
| December 31, 2018 | -71.22M |
| September 30, 2018 | 103.06M |
| June 30, 2018 | 253.68M |
| March 31, 2018 | 436.92M |
| December 31, 2017 | 68.40M |
| Date | Value |
|---|---|
| September 30, 2017 | 88.94M |
| June 30, 2017 | -50.22M |
| March 31, 2017 | -161.00M |
| December 31, 2016 | 133.27M |
| September 30, 2016 | 92.15M |
| June 30, 2016 | 128.26M |
| March 31, 2016 | 143.21M |
| December 31, 2015 | 188.92M |
| September 30, 2015 | 244.46M |
| June 30, 2015 | 552.03M |
| March 31, 2015 | 549.24M |
| December 31, 2014 | 549.24M |
| September 30, 2014 | 525.11M |
| June 30, 2014 | 180.88M |
| March 31, 2014 | 304.96M |
| December 31, 2013 | 248.41M |
| September 30, 2013 | 169.20M |
| June 30, 2013 | 164.34M |
| March 31, 2013 | 144.54M |
| December 31, 2012 | 172.20M |
| September 30, 2012 | -15.61M |
| June 30, 2012 | -3.694M |
| March 31, 2012 | -86.36M |
| December 31, 2011 | -124.24M |
| September 30, 2011 | 68.19M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-1.478B
Minimum
Dec 2021
126.80M
Maximum
Dec 2019
-496.40M
Average
-402.20M
Median
Sep 2023
Cash from Financing (TTM) Benchmarks
| Amgen Inc | 21.05B |
| Eli Lilly and Co | 3.496B |
| Regeneron Pharmaceuticals Inc | -1.790B |
| Alpine Immune Sciences Inc | 165.12M |
| Moderna Inc | -1.377B |